Option chain shows key data for AN2 Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AN2 Therapeutics.

AN2 Therapeutics (NASDAQ:ANTX) Stock, Option Chain

Anthem

AN2 Therapeutics

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

LEVI, Levi Strauss

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANTX

CNET

EONR

FLUX

GRFX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

KXIN

LEVI

MLGO

MYNA

NDRA

SNGX

VCIG

WHLR

Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket

Earnings

Earnings Beats

Large Cap

Penny Stocks

Small Cap

Analyst Ratings

ARCT

FULC

ILMN

AN2 Therapeutics (NASDAQ: ANTX), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.

AN2 Therapeutics Plunges 66% in a Month: Here&#39;s Why

penny stocks tips 1

Long Ideas

Insider Trades

RPHM

Citizens And 2 Other Penny Stocks Insiders Are Buying

AN2 Therapeutics Inc

Press Releases

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

Assertio Holdings

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

China Pharma Holding

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

IGC Pharma

Ikena Oncology

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

NRX Pharmaceuticals

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Citizens Capital Markets

JMP Securities

Evercore ISI Group

SVB Leerink

Comments

AN2 Therapeutics

AN2 Therapeutics (ANTX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell